Press Release

Pharma Two B Presents Positive Efficacy and Safety Data of P2B001 from Phase 3 Trial at the MDS International Congress of Parkinson’s Disease and Movement Disorders®

by

P2B001 is a novel proprietary fixed-dose combination of extended-release (ER) formulations of low doses of pramipexole and rasagiline; both doses are not currently available on the market Phase 3 data support the potential of P2B001 as a first-line, once-daily treatment for people with Parkinson’s disease (PD), that may offer effective symptomatic control with significantly less … Read more

Pharma Two B Presents Late-Breaker Abstract on Positive Efficacy and Safety Data of P2B001 from Phase 3 Trial at American Academy of Neurology (AAN) Annual Meeting

by

REHOVOT, Israel, April 05, 2022 (GLOBE NEWSWIRE) — Pharma Two B Ltd., a privately held company developing innovative therapeutics based on reformulation and combinations of previously approved drugs for neurological indications, today announced that the efficacy and safety data from its recently completed Phase 3, randomized controlled trial of P2B001 in the management of early Parkinson’s … Read more

Advances in Therapy publishes Pharma Two B’s review paper, “P2B001 (extended release pramipexole and rasagiline): A new treatment option in development for Parkinson’s disease”

by

Robert A. Hauser, Nir Giladi, Werner Poewe, Jonathan Brotchie, Hadas Friedman, Sheila Oren & Pninit Litman Published: 10 March 2022 Advances in Therapy DOI: 10.1007/s12325-022-02097-2 Abstract Despite levodopa’s superior efficacy in reducing the motor symptoms of Parkinson’s disease (PD), its risk to induce motor complications requires consideration of the pros and cons of initiating treatment … Read more

Pharma Two B Announces Positive Topline Results from its Pivotal Phase III Study of P2B001 in Early Parkinson’s Disease

by

Study successfully met its primary and key secondary endpoints, demonstrating superior efficacy of P2B001 compared to its individual components P2B001 showed comparable efficacy to a marketed extended release (ER) pramipexole with significantly less daytime sleepiness and a superior safety profile Topline results support P2B001’s potential as a first line treatment for people with early Parkinson’s … Read more

Pharma Two B Announces Licensing and Investment Agreement with Myung In Pharm (MIP) for P2B001 in South Korea

by

Myung In Pharm to lead registration, commercialization and manufacturing of P2B001 in South Korea Myung In Pharm made a $5 million equity investment in Pharma Two B REHOVOT, Israel, Nov. 18, 2021 (GLOBE NEWSWIRE) — Pharma Two B Ltd., a privately held company developing innovative therapeutics based on reformulation of previously approved drugs for neurological … Read more

Pharma Two B Appoints David S. Tierney, M.D. as the Company’s Chief Executive Officer

by

Rehovot, Israel – February 18, 2020 – Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs for Parkinson disease, announced today the appointment of David S. Tierney M.D. as Chief Executive Officer, effective immediately as well as the establishment of a fully owned U.S. subsidiary to serve as the … Read more

First Patients Dosed in Phase III Multi-center, Multinational Study to Determine the Efficacy, Safety and Tolerability of P2B001 in Patients with Early Stage Parkinson’s Disease

by

Based on positive data from a Phase IIb pivotal study suggesting that P2B001 may offer effective therapy with minimal side effects for early stage Parkinson’s Disease (PD) patients, Pharma Two B initiated a multinational Phase III clinical trial Rehovot, Israel – February 6th, 2018 – Pharma Two B Ltd., a privately held company developing innovative … Read more

© 2022 Pharma Two B

Thank you!

An email was sent with access to our exclusive materials.
Please check your inbox and spam folder.

Please subscribe for this

Get this exclusive content straight to your email

.